Zydus Life share rose after it received approval from USFDA to conduct Phase II(b) clinical trial for Usnoflast, a novel oral ...

The board approved the demerger of the consumer products division of Cadila Healthcare into Carnation, which is a subsidiary of Cadila Healthcare and the merger of Zydus Hospital and Medical ...

Other candidates in the pipeline include Bristol-Myers Squibb/Ambrx' BMS 986036, Horizon/Raptor Therapeutics' RP103 and Zydus Cadila's saroglitazar ... the first NASH products on the market ...

Zydus Lifesciences Limited (Formerly known as Cadila Healthcare Limited ... Active Pharmaceutical Ingredients (APIs) animal healthcare products and consumer wellness products. The Company operate ...

In contrast to peptides, where several LAI medicinal products have been successfully ... He has worked with Zydus Cadila, Cadila Pharma, Panacea Biotech, and Ipca Labs in different capacities.

Zydus Lifesciences Ltd. key Products/Revenue Segments include Pharmaceutical Products ... As on 31-12-2024, the company has a total of 100.62 Crore shares outstanding.Cadila Healthcare Share Price ...

Zydus Lifesciences announced that the USFDA granted Orphan Drug Designation to Usnoflast, a novel oral NLRP3 inhibitor, for ...

Ahmedabad: Zydus, a discovery-based, global pharmaceutical company has announced that the U.S. Food and Drug Administration ...

Zydus’ Usnoflast receives US FDA orphan drug designation to treat amyotrophic lateral sclerosis: Our Bureau, Mumbai Thursday, January 23, 2025, 12:15 Hrs [IST] Zydus, a leading, ...

Zydus Lifesciences announced that Usnoflast, a treatment for amyotrophic lateral sclerosis (ALS), has received Orphan Drug Designation from the US FDA. This designation supports the development of ...

The US Food and Drug Administration (FDA) has granted approval for Zydus Lifesciences to proceed with a randomised Phase IIb ...

Zydus received FDA approval to conduct a Phase 2b trial testing usnoflast, its oral therapy for ALS, in 210 patients.